Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFIRINOX
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
FOLFIRINOX is a combination chemotherapy regimen used primarily for the treatment of advanced pancreatic cancer, including metastatic and locally advanced (inoperable) cases. It consists of four drugs: - Folinic acid (leucovorin): a vitamin B derivative that enhances the effects of fluorouracil. - Fluorouracil (5-FU): an antimetabolite that disrupts DNA synthesis in rapidly dividing cells. - Irinotecan: a topoisomerase I inhibitor that prevents DNA from uncoiling and duplicating. - Oxaliplatin: a platinum-based agent that causes DNA crosslinking and damage. The regimen works by targeting cancer cells through multiple mechanisms to inhibit their growth and division. While it has demonstrated improved survival rates compared to other regimens like gemcitabine, it is associated with significant toxicity and is generally reserved for patients with good performance status. It may also be used as neoadjuvant therapy or in certain cases of bowel cancer[1][2][3][4][5].
- Brand names
- FOLFOXIRI
- Other names
- FOLFOXIRI
02
Targets
TOP1 (DNA Topoisomerase I)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on FOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFIRINOX.